JAK3 and renal cell carcinoma: Deregulation in JAK/STAT interaction promote tumorigenesis in haematological malignancies and epithelial tumors representing new therapeutic target [32, 33] and in our report we showed JAK3 mutations are associated with metastatic spread and poor survival of RCC patients [21].